{"entity":{"id":"nct06245889","kind":"trial","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","aka":["NeoADAPT"],"tldr":"A phase 2 trial of paclitaxel / nab-paclitaxel, carboplatin, pembrolizumab, doxorubicin and other drugs in triple-negative breast cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.","summary":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC is a phase 2, interventional study registered as NCT06245889 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 30 participants, started 2024-05-01 and due to reach its primary completion in 2029-06. Interventions recorded: Paclitaxel; Carboplatin; Pembrolizumab; Doxorubicin; Cyclophosphamide; Olaparib; Capecitabine. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Stage II-III TNBC - estrogen receptor (ER) and progesterone receptor (PR) up to and including 10% is eligible\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06245889","url":"https://clinicaltrials.gov/study/NCT06245889"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","parp-inhibitor","platinum"],"targets":[],"drugs":["paclitaxel","carboplatin","pembrolizumab","doxorubicin","cyclophosphamide","olaparib","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06245889","phase":"2","setting":"A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06245889/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}